Abiomed hits 52-week high

December 1, 2011 by MassDevice staff

Abiomed (NSDQ:ABMD) shares hit $20.25 apiece yesterday, their highest mark in 52 weeks, as the company touted more positive study results for its flagship Impella heart pump.

ABMD shares closed yesterday at $20.14, up 6.2 percent on a day of widespread gains on Wall Street. The Dow Jones Industrial Average gained 4.2 percent yesterday, the S&P 500 closed up 4.3 percent and the Dow Jones medical device index rose 4.8 percent.

The Danvers, Mass.-based cardiac assist device maker cited the publication of data from the USpella registry for its Impella pump, which is used to augment heart function in patients with heart disease. The new data, published in the Catheterization and Cardiovascular Interventions Journal, shows that the device helped high-risk patients during complex percutaneous coronary interventions such as stenting.

Sign up to get our free newsletters delivered right to your inbox

The researchers reviewed data from 175 subjects who underwent high-risk PCI with prophylactic support using Abiomed's Impella 2.5 device, looking for rates of major adverse cardiac events after 30 days and survival rates after a year. At 30-day follow-up, the rate of MACE was 8 percent; the survival rate at 12 months was 88 percent, according to the review.

"The use of Impella 2.5 in high-risk PCI appeared feasible and safe in the real-world setting. The utilization of the Impella 2.5 was successful, resulting in favorable short- and mid-term angiographic, procedural and clinical outcomes," the researchers wrote.

Permalink